ESAIY.US Eisai Co. Ltd.

Healthcare Pharmaceuticals USA Stocks
7.99 USD
Close of Nov 13, 2026
5.60 8.36
Market cap
USD 9.01B
P/E
32.0x
P/B
1.59x
ROE
8.2%
Dividend yield
3.18%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ESAIY.US undervalued?

Graham number
Price7.99
Graham value5.31
Premium50.5%

ESAIY.US trades 50.5% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Eisai Co. Ltd. fundamental analysis

No fundamental analysis for Eisai Co. Ltd. yet.

Eisai Co. Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Eisai Co. Ltd.

Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over…

Full company profile